SEQSTER has launched a partnership with CLEAR to provide patients with Individual Access Services and allow them to securely access, control, and share their personal health information with authorized users. SEQSTER has integrated the CLEAR platform to allow patients to confirm their identity, access their medical records, and safely share them with various clinical trial research organizations within the SEQSTER Operating System for healthcare.
With this partnership, patients can now affirm their identity—with a government-issued ID and a selfie—to create and manage their SEQSTER account. Once a SEQSTER patient verifies their identity and creates their account, they can securely share their personal health information with SEQSTER’s life sciences partners.
SEQSTER and CLEAR Forge Partnership to Drive Innovation and Improve Patient Outcomes with Real-World Data. (2023, April 17). EIN Presswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.